2.The Clinical Utility of Diffusion Tensor Imaging and Fiber Tractography for evaluating Diffuse Axonal Injury
Ken SUGIYAMA ; Takeo KONDO ; Yoshimi SUZUKAMO ; Minoru ENDO ; Hiroshi WATANABE ; Keiichiro SHINDO ; Shin-Ichi IZUMI
The Japanese Journal of Rehabilitation Medicine 2007;44(9):528-541
Diffuse axonal injury (DAI) is identified as one of the most important causes of cognitive disorders in patients with traumatic brain injury. Radiologic recognition of DAI can help in understanding the clinical syndrome and in making treatment decisions. However, CT and conventional MRI are often normal or demonstrate lesions that are poorly related to the cognitive disorders present. Recently, diffusion tensor imaging (DTI) and fiber tractography (FT) have been shown to be useful in detecting various types of white matter damage. The aim of this study was to evaluate the feasibility of using DTI and FT to detect lesions in DAI patients, and to correlate these DAI lesions with the patients' cognitive disorders. We investigated 9 normal volunteers and 9 patients with DAI. The DAI patients had impaired intelligence, as well as attention, memory and executive function disorders that restricted their activities of daily living. In the DAI patients, DTI showed abnormal brain areas in the corpus callosum, fornix, frontal and parietal lobe white matter, and FT revealed interruptions of the white matter fibers in the corpus callosum and the fornix when compared with the normal volunteers, while no lesions were found on conventional MRI. DTI and FT can directly visualize DAI lesions, which cannot be reliably detected by conventional methods. Accordingly, both DTI and FT may be useful techniques for the evaluation of DAI, and may have the potential to be applied to planning rehabilitation therapy, and predicting the neurologic prognosis in DAI patients with cognitive disorders.
3.Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma:the JGOG 3018 Trial
Takashi MOTOHASHI ; Akira YABUNO ; Hiroshi MICHIMAE ; Tetsuro OHISHI ; Miwa NONAKA ; Masashi TAKANO ; Shin NISHIO ; Hiroyuki FUJIWARA ; Keiichi KEIICHI ; Eiji KONDO ; Toru SUGIYAMA ; Tsutomu TABATA
Journal of Gynecologic Oncology 2021;32(1):e9-
Objective:
The standard dose for pegylated liposomal doxorubicin (PLD) is 50 mg/m2 every 4 weeks. While 40 mg/m2 has recently been used in clinical practice, evidence supporting this use remains lacking.
Methods:
This phase III randomized, non-inferiority study compared progressionfree survival (PFS) for patients with platinum-resistant ovarian carcinoma between an experimental arm (40 mg/m2 PLD) and a standard arm (50 mg/m2 PLD) until 10 courses, disease progression or unacceptable toxicity. Eligible patients had received ≤2 prior lines.Stratification was by performance status and PFS of prior chemotherapy (<3 months versus ≥3 months). The primary endpoint was PFS and secondary endpoints were overall survival (OS), toxicity profile, clinical response and tolerability. The total number of patients was 470.
Results:
The trial was prematurely closed due to slow recruitment, with 272 patients randomized to the experimental arm (n=137) and standard arm (n=135). Final analysis was performed with 234 deaths and 269 events for PFS. In the experimental arm vs. standard arm, median PFS was 4.0 months vs. 4.0 months (hazard ratio [HR]=1.065; 95% confidence interval [CI]=0.830–1.366) and median OS was 14.0 months vs. 14.0 months (HR=1.078; 95% CI=0.831–1.397). Hematologic toxicity and oral cavity mucositis (≥grade 2) were more frequent in the standard arm than in the experimental arm, but no difference was seen in ≥grade 2 hand-foot skin reaction.
Conclusion
Non-inferiority of 2 PLD dosing schedule was not confirmed because the trial was closed prematurely. However, recommendation of dose reduction of PLD should be based both on efficacy and safety.
4.The incidence and risk factors of venous thromboembolism in Japanese inpatients with inflammatory bowel disease: a retrospective cohort study.
Katsuyoshi ANDO ; Mikihiro FUJIYA ; Yoshiki NOMURA ; Yuhei INABA ; Yuuya SUGIYAMA ; Takuya IWAMA ; Masami IJIRI ; Keitaro TAKAHASHI ; Kazuyuki TANAKA ; Aki SAKATANI ; Nobuhiro UENO ; Shin KASHIMA ; Kentaro MORIICHI ; Yusuke MIZUKAMI ; Toshikatsu OKUMURA
Intestinal Research 2018;16(3):416-425
BACKGROUND/AIMS: Venous thromboembolism (VTE) is a major extraintestinal manifestation in inflammatory bowel disease (IBD), regarded as an independent risk factor for VTE according to reports from Western countries. However, the incidence and risk factors of VTE in Asian IBD patients are not fully understood. We aimed to reveal the incidence and risk factors of VTE in Japanese IBD inpatients. METHODS: The incidence of VTE in inpatients with IBD (n=340), gastrointestinal cancers (n=557), and other gastrointestinal diseases (n=569) treated at our hospital from 2009 to 2013 was retrospectively investigated. The characteristics and laboratory data of IBD inpatients with and without VTE were compared in univariate and multivariate analyses. Clinical courses of VTE in IBD were surveyed. RESULTS: VTE was detected in 7.1% of IBD inpatients, significantly higher than in gastrointestinal cancer inpatients (2.5%) and inpatients with other gastrointestinal diseases (0.88%). The incidence of VTE in ulcerative colitis (UC) patients (16.7%) was much higher than that in those with Crohn's disease (3.6%). In the univariate analysis, the risk factors were an older age, central venous catheter, prednisolone, surgery, low serum albumin, high serum C-reactive protein and D-dimer. According to a multivariate analysis, >50 years of age and surgery were the only risk factors. The in-hospital mortality rate of IBD inpatients with VTE was 4.2%. CONCLUSIONS: The incidence of VTE with IBD, especially UC, was found to be high compared with other digestive disease, which was almost equivalent to that of Western countries. The efficacy of prophylaxis needs to be investigated in Asian IBD patients.
Asian Continental Ancestry Group*
;
C-Reactive Protein
;
Central Venous Catheters
;
Cohort Studies*
;
Colitis, Ulcerative
;
Crohn Disease
;
Gastrointestinal Diseases
;
Gastrointestinal Neoplasms
;
Hospital Mortality
;
Humans
;
Incidence*
;
Inflammatory Bowel Diseases*
;
Inpatients*
;
Multivariate Analysis
;
Prednisolone
;
Retrospective Studies*
;
Risk Factors*
;
Serum Albumin
;
Venous Thromboembolism*
5.Long-term Observation of Gastric Adenocarcinoma of Fundic Gland Mucosa Type before and after Helicobacter pylori Eradication: a Case Report
Keitaro TAKAHASHI ; Nobuhiro UENO ; Takahiro SASAKI ; Yu KOBAYASHI ; Yuya SUGIYAMA ; Yuki MURAKAMI ; Takehito KUNOGI ; Katsuyoshi ANDO ; Shin KASHIMA ; Kentaro MORIICHI ; Hiroki TANABE ; Yuki KAMIKOKURA ; Sayaka YUZAWA ; Mishie TANINO ; Toshikatsu OKUMURA ; Mikihiro FUJIYA
Journal of Gastric Cancer 2021;21(1):103-109
Gastric adenocarcinoma of the fundic gland mucosa type (GA-FGM) was proposed as a new variant of gastric adenocarcinoma of the fundic gland type (GA-FG). However, at present, the influence of Helicobacter pylori and the speed of progression and degree of malignancy in GA-FGM remain unclear. Herein, we report the first case of intramucosal GA-FGM that was endoscopically observed before and after H. pylori eradication over 15 years. The lesion showed the same tumor size with no submucosal invasion and a low MIB-1 labeling index 15 years after its detection using endoscopy. The endoscopic morphology changed from 0-IIa before H. pylori eradication to 0-IIa+IIc and then 0-I after H. pylori eradication. These findings suggest that the unaltered tumor size reflects low-grade malignancy and slow growth, and that the endoscopic morphology is influenced by H. pylori eradication.
6.Report of the 71st Annual Meeting of the Japan Society for Oriental Medicine Special Program 1—“Pre-and Post-Graduate Kampo Medicine Education for the Next Generation”: Symposium on Model Core Curriculum in Medicine, Dentistry, Pharmacy and Nursing, and the Current Status of Kampo Education
Naoko HASUNUMA ; Yasuaki KAKINOKI ; Kazuyoshi KAWAZOE ; Atsuko SHIOTA ; Toshiaki KITA ; Kiyoshi SUGIYAMA ; Shin TAKAYAMA ; Tadamichi MITSUMA
Kampo Medicine 2022;73(4):434-447
At the 71st Annual Meeting of the Japan Society for Oriental Medicine in August 2021, we conducted a special program focusing on education in Kampo medicine, “Pre-graduate and post-graduate Kampo medicine education for the next generation.” As part of this project, we directed a symposium on the model core curriculum (core curriculum) in medicine, dentistry, pharmacy and nursing. The core curriculum in these fields includes Kampo education. Each institution shall promote education in accordance with the core curriculum, considering the characteristics of the field and the circumstances of the educational institution. We introduced the core curriculum in each field, and summarized and reported the current status of Kampo education in the field, points to note and suggestions for multidisciplinary cooperation, issues related to clinical practice and lack of educators, and future prospects.